Cargando…
Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy
An in vitro assay system using patient-derived tumor models represents a promising preclinical cancer model that replicates the disease better than traditional cell culture models. Patient-derived tumor organoid (PDO) and patient-derived tumor xenograft (PDX) models have been previously established...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020396/ https://www.ncbi.nlm.nih.gov/pubmed/33841567 http://dx.doi.org/10.3892/ol.2021.12667 |
_version_ | 1783674575128625152 |
---|---|
author | Takahashi, Nobuhiko Higa, Arisa Hiyama, Gen Tamura, Hirosumi Hoshi, Hirotaka Dobashi, Yuu Katahira, Kiyoaki Ishihara, Hiroya Takagi, Kosuke Goda, Kazuhito Okabe, Naoyuki Muto, Satoshi Suzuki, Hiroyuki Shimomura, Kenju Watanabe, Shinya Takagi, Motoki |
author_facet | Takahashi, Nobuhiko Higa, Arisa Hiyama, Gen Tamura, Hirosumi Hoshi, Hirotaka Dobashi, Yuu Katahira, Kiyoaki Ishihara, Hiroya Takagi, Kosuke Goda, Kazuhito Okabe, Naoyuki Muto, Satoshi Suzuki, Hiroyuki Shimomura, Kenju Watanabe, Shinya Takagi, Motoki |
author_sort | Takahashi, Nobuhiko |
collection | PubMed |
description | An in vitro assay system using patient-derived tumor models represents a promising preclinical cancer model that replicates the disease better than traditional cell culture models. Patient-derived tumor organoid (PDO) and patient-derived tumor xenograft (PDX) models have been previously established from different types of human tumors to recapitulate accurately and efficiently their tissue architecture and function. However, these models have low throughput and are challenging to construct. Thus, the present study aimed to establish a simple in vitro high-throughput assay system using PDO and PDX models. Furthermore, the current study aimed to evaluate different classes of anticancer drugs, including chemotherapeutic, molecular targeted and antibody drugs, using PDO and PDX models. First, an in vitro high-throughput assay system was constructed using PDO and PDX established from solid and hematopoietic tumors cultured in 384-well plates to evaluate anticancer agents. In addition, an in vitro evaluation system of the immune response was developed using PDO and PDX. Novel cancer immunotherapeutic agents with marked efficacy have been used against various types of tumor. Thus, there is an urgent need for in vitro functional potency assays that can simulate the complex interaction of immune cells with tumor cells and can rapidly test the efficacy of different immunotherapies or antibody drugs. An evaluation system for the antibody-dependent cellular cytotoxic activity of anti-epidermal growth factor receptor antibody and the cytotoxic activity of activated lymphocytes, such as cytotoxic T lymphocytes and natural killer cells, was constructed. Moreover, immune response assay systems with bispecific T-cell engagers were developed using effector cells. The present results demonstrated that in vitro assay systems using PDO and PDX may be suitable for evaluating anticancer agents and immunotherapy potency with high reproducibility and simplicity. |
format | Online Article Text |
id | pubmed-8020396 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-80203962021-04-10 Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy Takahashi, Nobuhiko Higa, Arisa Hiyama, Gen Tamura, Hirosumi Hoshi, Hirotaka Dobashi, Yuu Katahira, Kiyoaki Ishihara, Hiroya Takagi, Kosuke Goda, Kazuhito Okabe, Naoyuki Muto, Satoshi Suzuki, Hiroyuki Shimomura, Kenju Watanabe, Shinya Takagi, Motoki Oncol Lett Articles An in vitro assay system using patient-derived tumor models represents a promising preclinical cancer model that replicates the disease better than traditional cell culture models. Patient-derived tumor organoid (PDO) and patient-derived tumor xenograft (PDX) models have been previously established from different types of human tumors to recapitulate accurately and efficiently their tissue architecture and function. However, these models have low throughput and are challenging to construct. Thus, the present study aimed to establish a simple in vitro high-throughput assay system using PDO and PDX models. Furthermore, the current study aimed to evaluate different classes of anticancer drugs, including chemotherapeutic, molecular targeted and antibody drugs, using PDO and PDX models. First, an in vitro high-throughput assay system was constructed using PDO and PDX established from solid and hematopoietic tumors cultured in 384-well plates to evaluate anticancer agents. In addition, an in vitro evaluation system of the immune response was developed using PDO and PDX. Novel cancer immunotherapeutic agents with marked efficacy have been used against various types of tumor. Thus, there is an urgent need for in vitro functional potency assays that can simulate the complex interaction of immune cells with tumor cells and can rapidly test the efficacy of different immunotherapies or antibody drugs. An evaluation system for the antibody-dependent cellular cytotoxic activity of anti-epidermal growth factor receptor antibody and the cytotoxic activity of activated lymphocytes, such as cytotoxic T lymphocytes and natural killer cells, was constructed. Moreover, immune response assay systems with bispecific T-cell engagers were developed using effector cells. The present results demonstrated that in vitro assay systems using PDO and PDX may be suitable for evaluating anticancer agents and immunotherapy potency with high reproducibility and simplicity. D.A. Spandidos 2021-05 2021-03-22 /pmc/articles/PMC8020396/ /pubmed/33841567 http://dx.doi.org/10.3892/ol.2021.12667 Text en Copyright: © Takahashi et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Takahashi, Nobuhiko Higa, Arisa Hiyama, Gen Tamura, Hirosumi Hoshi, Hirotaka Dobashi, Yuu Katahira, Kiyoaki Ishihara, Hiroya Takagi, Kosuke Goda, Kazuhito Okabe, Naoyuki Muto, Satoshi Suzuki, Hiroyuki Shimomura, Kenju Watanabe, Shinya Takagi, Motoki Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy |
title | Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy |
title_full | Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy |
title_fullStr | Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy |
title_full_unstemmed | Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy |
title_short | Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy |
title_sort | construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020396/ https://www.ncbi.nlm.nih.gov/pubmed/33841567 http://dx.doi.org/10.3892/ol.2021.12667 |
work_keys_str_mv | AT takahashinobuhiko constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy AT higaarisa constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy AT hiyamagen constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy AT tamurahirosumi constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy AT hoshihirotaka constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy AT dobashiyuu constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy AT katahirakiyoaki constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy AT ishiharahiroya constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy AT takagikosuke constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy AT godakazuhito constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy AT okabenaoyuki constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy AT mutosatoshi constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy AT suzukihiroyuki constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy AT shimomurakenju constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy AT watanabeshinya constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy AT takagimotoki constructionofinvitropatientderivedtumormodelstoevaluateanticanceragentsandcancerimmunotherapy |